ASLAN Pharmaceuticals (ASLN)
(Real Time Quote from BATS)
$0.43 USD
0.00 (0.30%)
Updated Jun 3, 2024 02:02 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
ASLAN Pharmaceuticals Ltd. [ASLN]
Reports for Purchase
Showing records 61 - 80 ( 102 total )
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Recruitment Paused; Interruption Transient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Shows Preliminary Efficacy in Eczema; Financing Closed; Reiterate Buy; Raising PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Preclinical Data of ASLAN003 in AML Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
TreeTopp Missed; Eczema Data Next; Reiterate Buy; Reducing PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
3Q Financial Results; TREETOPP Data Readout Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Proof-of-Concept Atopic Dermatitis Study Starts Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Investigator-Initiated Phase 1b Results in Advanced Solid Tumors Presented at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Joint Venture Established on Early-Stage AhR Antagonists; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Data From Phase 2a Biliary Tract Cancer Study in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Reiterate Buy; Modulating Price Target to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Single Ascending Dose Study of ASLAN004 Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Full Global Commercial Rights to ASLAN004 Acquired; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Phase 1 Data of ASLAN004 Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
New BioGenetics Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Varlitinib South Korean Commercialization Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Clinical Program Prioritization, Corporate Restructuring Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R